LBA-1 First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

Z Wainberg,T Bekaii-Saab,P Boland,F Dayyani,T Macarulla,K Mody,B Belanger,F Maxwell,Y Moore,A Thiagalingam,T Wang,B Zhang,A Dean

doi:10.1016/j.annonc.2020.04.076

LBA-1 First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

Z Wainberg, T Bekaii-Saab + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2020.04.076

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2020
Citations: 8	License type: publisher-specific-oa

Affiliation: University of California, Los Angeles, Mayo Clinic Hospital, Phoenix (United States), Rutgers, The State University of New Jersey, University of California, Irvine Medical Center, Vall d'Hebron Institute of Oncology, Jacksonville College, Mayo Clinic, Winneshiek Medical Center, Ipsen (United States), Ipsen (United Kingdom), St John of God Subiaco Hospital

#Liposomal Irinotecan #Metastatic Pancreatic Ductal Adenocarcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Liposomal irinotecan + 5‑fluorouracil/leucovorin (5-FU/LV) is approved for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) following progression with gemcitabine-based therapy. We report long-term follow-up results (data cut-off 26 Feb 2020) from an open-label phase 1/2 study (NCT02551991; EudraCT 2015-003086-28) of adults with previously untreated, unresectable, locally advanced/metastatic PDAC receiving liposomal irinotecan + 5-FU/LV + oxaliplatin (NALIRIFOX).

Full Text